Generics to double?
May 11, 2010
MARKETING analysts from
Datamonitor have predicted that
the cardiovascular and metabolic
generic market will more than
double the size of its branded
counterpart in just eight years time.
The comments come on the back
of a recent Datamonitor report
which found that dyslipidemia is the
disease area that will show the
highest generic growth by 2018.
This coupled with recent patent
expiries for some dyslipidemia drugs
as well as the upcoming expiries for
both Lipitor (atorvastatin) and
Crestor (rosuvastatin) will be the
backbone of this projected growth.
“As the market becomes more
genericised, the average price of
generics drops and more patients
choose to, or are able to, purchase
cardiovascular drugs,” said
Datamonitor’s Gideon Heap.
Generic manufacturers sizing
their potential markets should be
aware they are competing not just
for the population currently taking
a drug, but “potentially others who
only have access to lower priced
drugs,” Heap added.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 May 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 May 10
